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N TRADITIONAL HOSPITAL PRACTICE most of the burden of drug therapy decision making falls on the physician. However, studies have shown that physicians sometimes make errors in prescribing drugs.
1,2 While most errors are harmless or are intercepted, some result in adverse drug events (ADEs). The pharmacist's role in prescribing is typically reactive: responding to prescription errors long after the decision has been made for patients about whom he or she has little direct clinical knowledge. Thus, the specialized knowledge of the pharmacist is not utilized when it would be most useful: at the time of ordering.
Studies show that pharmacist retrospective review of medication orders prevents errors. [3] [4] [5] However, the pharmacist's impact might be substantially greater if he or she could provide input earlier, at the time of prescribing. It has been shown that pharmacist consultation with physicians and others in an intensive care unit (ICU) resulted in a net saving from reduced drug use of $10 011 in a 3-month period. 6 How-ever, we know of no controlled studies that have evaluated the effect of pharmacist participation on the key outcome measure of error preventionthe rate of ADEs. For these reasons, we conducted a controlled clinical trial of the efficacy of pharmacist participation in physician rounds in a medical ICU as part of a continuing study of systems changes to prevent ADEs. The ADE rate is higher among patients in ICUs, both because they have pathophysiological abnormalities and often receive many drugs.
We asked the following questions: (1) Is pharmacist participation on rounds associated with a reduction in the rate of preventable ADEs? (2) What types of interventions does the pharmacist make? and (3) Is pharmacist participation on ICU rounds accepted by physicians and nurses?
METHODS
The study was carried out in 2 medical ICUs at Massachusetts General Hospital, a large tertiary care hospital in Boston, during 2 periods: February 1, 1993, through July 31, 1993 (phase 1, preintervention), and October 1, 1994, through July 7, 1995 (phase 2, postintervention).
The study unit was a 17-bed medical ICU and the control unit was a 15-bed coronary care unit (CCU). The average daily census was 13.9 in the medical ICU and 12.9 in the CCU during phase 1 and 12.4 and 11.9, respectively, during phase 2. Nurse and physician staffing ratios were similar in the 2 units. Patients in the medical ICU had a range of acute and chronic medical illness other than primary cardiac disease, while those in the CCU were primarily cardiac patients. Each unit frequently admitted both categories of patients when the other unit was full. Patients receiving ventilatory support constituted 70% of patients in the medical ICU and 60% of patients in the CCU.
Sample
We compared outcomes in the study unit before and after the intervention, and between the study unit and a control unit during the same period after the intervention. Using a random number generator, we selected 75 patients from each of 3 groups: all patients admitted to the study unit during phase 1 and phase 2 and all patients admitted to the control unit during phase 2. To detect whether unmeasured variables may have altered the rate of ADEs (secular trend), we also randomly selected 50 patients from all those admitted to the control unit during phase 1.
The intervention was the assignment of an experienced senior pharmacist to make rounds with the patient care team in the study ICU. The pharmacist made rounds with the residents, nurses, and attending staff each morning, was present in the unit for consultation and assistance to the nursing staff during the rest of the morning, and was available on call as necessary throughout the day. The total commitment was approximately half of the pharmacist's time. In the control ICU, as is the usual practice, another pharmacist was available in the unit for part of the day but did not make rounds with physicians and nurses. The intervention began in May 1994. Data collection began in October 1994 and continued through July 1995.
Outcome Measures
We assessed the effect of pharmacist participation with 2 measures: (1) the change in the rate of preventable ADEs in the ordering stage and (2) the number and acceptance of interventions recommended by the pharmacist. We defined an ADE as an injury related to the use of a medication. A preventable ADE is an injury caused by an error in the use of a medication (eg, hypotension or hypoglycemia, changes in mental status, bleeding, or cardiac arrest). 
Adverse Drug Events
Using previously described methods, 7 trained and experienced investigators (1 nurse and 1 pharmacist) identified incidents (apparent medication errors or ADEs) by review of medical records in which they examined all progress notes, orders, and laboratory results during the index admission.
Incidents were evaluated independently by 2 physician reviewers (L.L.L. and D.W.B.) who classified them according to whether or not an ADE or potential ADE was present. Using preestablished criteria, 7 they also made judgments of severity, preventability, and, if an error was present, the type of error and the stage in the process at which the error occurred. When there were disagreements the reviewers met and reached consensus. If consensus could not be reached, a third reviewer evaluated the incident. Reliability for these judgments has previously been reported 7 (for judgments about whether an incident was an ADE, = 0.81-0.98; for preventability, = 0.92; and for severity, = 0.32-0.37). All reviewers and investigators were blinded to patient group assignment.
Pharmacist Interventions
To develop descriptive information about changes suggested by the pharmacist, we measured the number of interventions, the type of intervention, and the percentage of recommendations accepted. For this purpose, the pharmacist completed a report form for each intervention that could potentially lead to a change in orders, noting the date, drug, nature of the order, the specific recommendation, and whether or not it was accepted by the physicians. The type of intervention was then classified as shown in TABLE 1. The pharmacist also recorded events that did not involve order changes, such as errors in the pharmacy system or identification of ADEs.
Analysis
The primary measure used to assess the effect of the interventions was the rate of preventable ADEs due to prescribing errors. We conducted comparisons at 2 points in time in the study unit, before and after the intervention, and between the study and control units after the intervention.
For the before-after evaluation, we compared the rate of occurrence of preventable ordering ADEs among patients in the study unit during phase 1 PHARMACIST PARTICIPATION IN THE INTENSIVE CARE UNIT with the rate in the same unit during phase 2. For the between-unit comparison, we compared the rate in the study unit during phase 2 with the rate of occurrence in the control unit in phase 2. To assess potential secular trends, we also compared the rate in the control unit in phase 1 with its rate in phase 2.
Comparisons between rates in phases 1 and 2 in the study unit (before and after) and between the study unit and the control unit in phase 2 (contemporaneous) were made using unpaired t tests. Analyses were performed using SAS statistical software.
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RESULTS
ADE Rates
The overall rates, expressed as preventable ordering ADEs per 1000 patientdays, are shown for both phases for both units in TABLE 2. In the before and after comparison, the rate of preventable ordering ADEs per 1000 patientdays decreased in the study unit by 66% from phase 1 to phase 2 (10.4 [95% CI, 7-14] to 3.5 [95% CI, 1-5]; PϽ.001).
When the intervention unit was compared with the control unit during the same time period (phase 2), the rate of preventable ordering ADEs in the study unit was 72% lower than in the control unit (3. When results were calculated in terms of number of patients (admissions), the differences in rates were similar: in the study unit, the rate of preventable ordering ADEs decreased by two thirds, from 12% in phase 1 to 4% in phase 2, while it was essentially unchanged in the control unit (10% to 11%).
The rate of all ADEs also decreased substantially in the study unit from phase 1 to phase 2 (33. 
Pharmacist Interventions
During phase 2, a total of 398 pharmacist interventions were recorded (Table  1) . Of these, 366 were related to ordering, of which 362 (99%) were accepted by the physicians. Nearly half (178/389 [46%]) were pharmacist-initiated clarification or correction of a proposed or previous order. These errors included incomplete orders, wrong dose, wrong frequency, inappropriate choice, and duplicate therapy. Examples were a recommendation to reduce the dose of intravenous phenytoin from 300 mg 3 times per day, the correct oral dose, to 100 mg 3 times per day and reduction of the dose of ampicillin administered to a patient with renal failure.
In 100 instances, the pharmacist provided drug use information, most often at the time the decision was being made about whether to order a drug. Examples were education of the house staff on the selection of sedatives in patients receiving ventilatory support and the risk of extrapyramidal adverse effects from excessive doses of droperidol.
The pharmacist recommended alternative therapy in 47 cases, suggesting drugs that were safer or cheaper but equally effective, such as changing from intravenous to oral metoclopromide. Potential problems relating to drug interactions and drug allergies were identified by the pharmacist in 22 cases and use of alternative drugs was recommended.
Thirty-two of the pharmacist interventions did not relate to ordering. Among these, the pharmacist provided special order drugs or approved nonformulary use of a drug in 14 instances, identified 6 previously unrecognized ADEs, and uncovered 12 systems errors in the pharmacy dispensing system. One example of dispensing errors was that a medication was prepared for peripheral intravenous infusion when a smaller volume was required for central administration to minimize fluid load.
COMMENT
In previous studies, we demonstrated that nearly half of preventable ADEs resulted from errors in the prescribing process. 1 Prescribing errors frequently have a cascade effect, causing errors downstream in dispensing or administration. The major cause of prescribing errors was physicians' lack of essential drug *Percentages sum to more than 100% because of rounding. †Four dose corrections recommended by the pharmacist were not accepted by the physicians. All were recommendations for dose reduction in patients with some evidence of renal failure. Three of the 4 were immunocompromised patients (acquired immunodeficiency syndrome, leukemia, and lung transplantation) for whom the physicians believed the benefit of continued treatment outweighed the risk of drug toxicity or further renal damage. All were carefully monitored and none suffered progressive damage. and patient information at the time of ordering. 2 One method of providing such information is computerized physician order entry, which has been shown to reduce the rate of serious medication errors by more than half. 9 Evans et al 10 have demonstrated that a computerassisted management program for antibiotics can substantially reduce excessive use and misuse of antibiotics as well as reduce length of hospital stay and costs. However, most hospitals do not yet have computerized ordering by physicians, so incorporation of the pharmacist into the patient care team is a more feasible alternative at present, especially in units with high medication use. We estimated the financial impact of the 66% reduction in ADEs. The cost of an ADE has been estimated at $2000 to $2500 per event in 1993. 11, 12 However, the cost of a preventable ADE, one due to an error, was estimated at $4685. 9 For the year 1995 , we estimate that 58 ADEs were prevented. At $4685 each, the cost reduction in this single unit would be approximately $270 000 per year. The intervention required no additional resources and represented a different use of the existing pharmacist's time. Rather than spending time checking and correcting orders after they had been sent to the pharmacy, the pharmacist was involved at the time the order was written. While participating in rounds as a member of the patient care team, the pharmacist reduced ADEs both by preventing errors and by intercepting them. He prevented errors by providing information about doses, interactions, indications, and drug alternatives to physicians at the time of ordering. He intercepted errors by immediately reviewing all orders and correcting deficiencies before the orders were transmitted to the pharmacy. In addition, the pharmacist prevented nursing medication errors by providing ready consultation to the nursing staff and teaching drug safety.
Finally, the on-site pharmacist took overall responsibility for medication safety, spotting unsafe conditions and identifying needs for process improvement. For example, during the study period the pharmacist identified 12 systems errors in pharmacy function and 6 ADEs that probably would not have otherwise been discovered.
The presence of the pharmacist on rounds was well accepted by physicians, as evidenced by the fact that 99% of the recommendations were accepted. While staff perceptions were not evaluated systematically, in our experience, nurses also accepted this role easily, appreciating the reduction in extra work, such as telephoning physicians to have orders corrected. The pharmacist in this study had to overcome the traditional impression of the medical staff that pharmacists may be primarily concerned with costs. This academic medical ICU environment had the added challenge of dealing with a new group of house staff, fellows, and attending physicians every few weeks. In ICUs where the attending physicians are permanent and fellows are assigned for many months, acceptance might be enhanced.
Our study has several limitations. We studied only 1 ICU in 1 teaching hospital. Adverse drug events are more common in teaching hospitals than in community hospitals 13 and occur more frequently in ICUs, 1 so these findings are not generalizable to all types of units or all types of hospitals. However, the magnitude of the impact of the pharmacist's presence was so great that a substantial effect would probably be found in ICUs in other hospitals. Second, our results do not represent the full extent of preventable ADEs, since record review does not capture all events, nor does it capture most potential ADEs, the "near misses," because they are seldom recorded in patient charts. Third, physicians and nurses in this ICU function as a team and make rounds together. Pharmacist participation would be more difficult to arrange in units where multiple physicians make rounds at different times. Finally, the success of the pharmacist intervention depends on interpersonal relationships. Thus, the personality and cooperativeness of the pharmacist and the medical staff are critical factors in making this system work, especially at the beginning. Similar prevention of ADEs prompted by a designated ICU pharmacist probably would be less likely to occur in ICUs in which staff are not part of a multidisciplinary team and when ICU staff are not open to the important role that the pharmacist can play in optimizing ICU management.
We conclude that participation of a pharmacist on medical rounds can be a powerful means of reducing the risk of ADEs.
